Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Pfizer's Xianyida (ecnoglutide) wins China approval for obesity treatment targeting GLP-1 receptor following Ph3 results
Protein therapy, metabolic, GLP-1 receptor agonist, obesity, type 2 diabetes - Read more

FDA expands Bristol Myers Squibb's Sotyktu (deucravacitinib) approval to psoriatic arthritis following Ph3 success
Small molecule, autoimmune, TYK2 inhibitor, psoriatic arthritis, oral therapy - Read more

Incyte's Zynyz (retifanlimab) wins European Commission approval for advanced squamous cell carcinoma of anal canal treatment
Antibody, cancer, PD-1 inhibitor, squamous cell carcinoma, combination therapy - Read more

Lonza sells capsule business to Lone Star Funds for $3B, retains 40% stake
Divestiture, manufacturing, CDMO, equity investment, private equity - Read more

Sanofi, EMS strike deal to sell generics manufacturer Medley for above $500M
Acquisition, generics, divestiture - Read more

Medtronic, GE HealthCare extend multiyear partnership to expand wireless wearables and anesthesia technologies
Technology partnership, medical devices, patient monitoring, wireless wearables - Read more

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

Roche's Gazyva (obinutuzumab) shows Ph3 success in systemic lupus erythematosus targeting anti-CD20 pathway
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, CD20 target, steroid sparing - Read more

Hansoh Pharmaceutical's olatorepatide (HS-20094) achieves 19.3% weight loss in Ph3 obesity trial with improved tolerability
Protein therapy, metabolic, GLP-1/GIP dual agonist, obesity, weight loss - Read more

EVerZom raises €10M ($11.6M) Series A, exosome-based biotherapies for inflammatory diseases
Alzheimer disease, neurological, neurostimulation device, clinical-stage - Read more

Solid Biosciences raises $240M private placement for neuromuscular/cardiac genetic medicines development
Gene therapy, neuromuscular, cardiac diseases, precision medicine - Read more

Servier acquires Day One Biopharmaceuticals for $2.5B to expand childhood brain tumor portfolio with Ojemda
Small molecule, oncology, strategic, major transaction - Read more

Taiwan earmarks $755M for four-year pharmaceutical resilience program to boost domestic drug production capacity
Strategic, supply chain resilience, pharmaceutical manufacturing, national security - Read more

FDA to review AstraZeneca's oral SERD camizestrant and Truqap indication in April advisory committee meeting
Oral SERD, oncology, regulatory, strategic - Read more

Merck KGaA explores China partnerships for new medicines and technologies development
Strategic partnership, drug discovery, life sciences, healthcare technology - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Beam Therapeutics retains base editing technology through revised Kobe University license amid Bio Palette dissolution
Licensing deal, base editing, gene therapy, cell therapy, royalties - Read more

Invea Therapeutics withdraws $35M IPO, developing oral small molecules for inflammatory diseases
Inflammatory disease, small molecule, oral therapeutics, preclinical - Read more

Democrats press 11 pharmas including AbbVie, Amgen for evidence Trump MFN deals deliver Medicaid savings
Pharmaceutical pricing, regulatory, strategic, financial - Read more

FDA's Vinay Prasad to depart CBER director role in April amid workplace toxicity probe
Regulatory, operational, strategic, leadership - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here